Dr Berdeja speaks with at EHA 23 about a clinical trial of bb2121, a second generation CAR T cell for relapsed myeloma.

He describes response rates among a heavily pretreated patient cohort, and introduces the upcoming expansion KarMMa trial which is recruiting now

For more information, watch his presentation of these results at a press session here.

ecancer's filming has been kindly supported by Amgen through the ecancer Global Foundation. ecancer is editorially independent and there is no influence over content.